Intervention with methotrexate in patients with arthralgia at risk of rheumatoid arthritis to reduce the development of persistent arthritis and its disease burden (TREAT EARLIER): a randomised, double-blind, placebo-controlled, proof-of-concept trial-Reference-Cited by-同舟云学术

Intervention with methotrexate in patients with arthralgia at risk of rheumatoid arthritis to reduce the development of persistent arthritis and its disease burden (TREAT EARLIER): a randomised, double-blind, placebo-controlled, proof-of-concept trial

Published:2022-07 Issue:10348 Volume:400 Page:283-294
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Krijbolder Doortje I,Verstappen Marloes,van Dijk Bastiaan T,Dakkak Yousra J,Burgers Leonie E,Boer Aleid C,Park Yune Jung,de Witt-Luth Marianne E,Visser Karen,Kok Marc R,Molenaar Esmeralda T H,de Jong Pascal H P,Böhringer Stefan,Huizinga Tom W J,Allaart Cornelia F,Niemantsverdriet Ellis,van der Helm-van Mil Annette H M

Funder

Leids Universitair Medisch Centrum

Dutch Arthritis Society

ZonMw

Nederlandse Organisatie voor Wetenschappelijk Onderzoek

Publisher

Elsevier BV

Subject

General Medicine

Reference30 articles.

1. Predictors of work disability during the first 3 years after diagnosis in a national rheumatoid arthritis inception cohort;Olofsson;Ann Rheum Dis,2014

2. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update;Smolen;Ann Rheum Dis,2020